Trudeau Institute, Ampersand Biosciences producing tools for flu research with $1M grant
SARANAC LAKE — Local research and biotechnology laboratories Trudeau Institute and Ampersand Biosciences have received a $1 million grant to produce tools aiding the research of the flu.
The $1,084,824 grant is a second-phase Small Business Innovative Research grant from the National Institute of Allergy and Infectious Diseases, which is part of the National Institutes of Health. This builds on two previous phase-one SBIR awards the two laboratories received to generate reagents for studying infectious diseases like the flu or coronavirus.
Reagents are molecules that make it easier for scientists to test what is happening in test animals' immune systems when they are infected with the flu — and what happens when they get treatment or a vaccine. In this case, the reagents are proteins, specifically, monoclonal antibodies. After the reagents are created and validated, Ampersand sells them to the scientific community to be used in more research.
This second phase will be a two-year study digging deeper into testing some of these molecules.
FLU DEATHS
Deb Brown, principal investigator at Saranac Lake-based Trudeau Institute, said what they produce will be a tool for the whole influenza research community.
The flu causes close to 500,000 deaths annually worldwide. It's a common viral disease, known for causing lethargy, difficulty in breathing and high fevers. According to the World Health Organization, there are around 1 billion cases of the flu worldwide annually, with 3 to 5 million causing severe illness. According to the WHO, 99% of flu-related deaths are in children under the age of 5, mostly in developing countries. In the United States, the flu causes around 36,000 deaths each year. Here, 90% of these deaths are in people 65 or older.
Brown's influenza lab at Trudeau Institute already studies the disease in mice. Now, they'll use ferrets.
Ferrets are better than mice for researching influenza for several reasons. For one, ferrets have lungs which are more similar to human lungs than mice. Also, ferrets have a much stronger sneeze reflex than mice. This allows them to study the spread of the disease and vaccine responses better, because infected ferrets can transmit the flu to each other.
REAGENT KITS
Dr. Tori Race is the principal investigator at Lake-Clear based Ampersand Biosciences. Ampersand specializes in the development of reagents and sells them in kits.
A $596,519 grant in 2020 led to the development of 14 different reagents to detect 'biomarkers' in animals. Biomarkers are molecules in blood and tissue which signal infection. These reagents are currently being sold by Ampersand to support research on diseases like influenza and COVID-19. This is the first time these molecules have been available to the research community.
The first phase took a 'tremendous amount of work,' Race said.
Part of the second phase is to make these reagent tools available for more researchers. Currently, they are used in a specialized and expensive machines. Now, the laboratories are working to make these tools usable with less expensive and more common machines.
Though the tools they're producing can't be used in human studies, the lessons learned can be adapted to apply to human studies.
FIGHTING CYTOKINE STORMS
Brown said one of the things the researchers will use the reagents for is to see if there's less of an inflammatory response, or cytokine storm, when treated with vaccines or therapeutic drugs.
A cytokine storm is an extreme immune response to infection with rapid inflammation. It is a cause of severe and fatal cases of the flu or COVID-19. Essentially, the immune system is overreacting to the infection, which inhibits breathing.
'Researchers are trying to develop therapeutics to combat this, so now we can test for that in these better animal models,' Brown said.
Brown's work focuses on making flu vaccines more universal, to protect against many different strains of the illness, instead of just the one that's around in a given year. For all the scientific advancement in vaccines, she said we still don't have good vaccines for the flu. Strategies which worked for diseases like small pox, measles and mumps don't work for influenza because it changes and mutates so rapidly.
She is interested in looking at the bodily immune response to the virus, and using that knowledge to develop better vaccines. Part of this new grant is meant to use new methods that can detect both the type of immune cell in the lung, as well as that cell's function.
'Can we design a vaccine that acts more like our own immune response?' Brown asked, 'to provide protection against more than just the viruses that are circulating year-to-year.'
REASONS TO CELEBRATE
She said it feels great to provide brand-new information and research for the whole immunology community. Not everyone has the ability to do research with ferrets, so others rely on places like Trudeau Institute to provide that research.
'There's an immense sense of pride, honestly,' Race said. 'Whenever a kit is ordered we celebrate.'
They have a world map on the wall of their offices and place a push-pin on cities wherever they've sold kits. So far, they've sold more than 70 ferret multiplex kits.
'While it seems modest, these sales mean a lot to our small business of seven people,' Race said. 'Any additional minds we have working on the development of vaccines and therapeutics in this important area, the better.'
The National Institutes of Health and Centers for Disease Control and Prevention are some of Ampersand's biggest customers.
Brown said it's neat to have a bio-tech hub with Trudeau, Ampersand and Bionique Testing Laboratories all in the Saranac Lake area. Race said they collaborate with Trudeau as often when they can.
Undergraduate students from Hamilton College just started helping Brown with her work on mouse influenza models this week.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
12 minutes ago
China rushes to build out solar, emissions edge downward
TALATAN, China -- High on the Tibetan plateau, Chinese government officials last month showed off what they say will be the world's largest solar farm when completed — 610 square kilometers (235 square miles), the size of the American city of Chicago. China has been installing solar panels at a blistering pace, far faster than anywhere else in the world, and the investment is starting to pay off. A study released Thursday found that the country's carbon emissions edged down 1% in the first six months of the year compared to a year earlier, extending a trend that began in March 2024. The good news is China's carbon emissions may have peaked well ahead of a government target of doing so before 2030. But China, the world's biggest emitter of greenhouse gases, will need to bring them down much more sharply to play its part in slowing global climate change. For China to reach its declared goal of carbon neutrality by 2060, emissions would need to fall 3% on average over the next 35 years, said Lauri Myllyvirta, the Finland-based author of the study and lead analyst at the Centre for Research on Energy and Clean Air. 'China needs to get to that 3% territory as soon as possible,' he said. China's emissions have fallen before during economic slowdowns. What's different this time is electricity demand is growing — up 3.7% in the first half of this year — but the increase in power from solar, wind and nuclear has easily outpaced that, according to Myllyvirta, who analyzes the most recent data in a study published on the U.K.-based Carbon Brief website. 'We're talking really for the first time about a structural declining trend in China's emissions,' he said. China installed 212 gigawatts of solar capacity in the first six months of the year, more than America's entire capacity of 178 gigawatts as of the end of 2024, the study said. Electricity from solar has overtaken hydropower in China and is poised to surpass wind this year to become the country's largest source of clean energy. Some 51 gigawatts of wind power was added from January to June. Li Shuo, the director of the China Climate Hub at the Asia Society Policy Institute in Washington, described the plateauing of China's carbon emissions as a turning point in the effort to combat climate change. 'This is a moment of global significance, offering a rare glimmer of hope in an otherwise bleak climate landscape,' he wrote in an email response. It also shows that a country can cut emissions while still growing economically, he said. But Li cautioned that China's heavy reliance on coal remains a serious threat to progress on climate and said the economy needs to shift to less resource-intensive sectors. 'There's still a long road ahead,' he said. A seemingly endless expanse of solar panels stretches toward the horizon on the Tibetan plateau. White two-story buildings rise above them at regular intervals. Sheep graze on the scrubby vegetation that grows under them. Solar panels have been installed on about two-thirds of the land. When completed, it will have more than 7 million panels and be capable of generating enough power for 5 million households. Like many of China's solar and wind farms, it was built in the relatively sparsely populated west. A major challenge is getting electricity to the population centers and factories in China's east. 'The distribution of green energy resources is perfectly misaligned with the current industrial distribution of our country,' Zhang Jinming, the vice governor of Qinghai province, told journalists on a government-organized tour. Part of the solution is building transmission lines traversing the country. One connects Qinghai to Henan province. Two more are planned, including one to Guangdong province in the southeast, almost at the opposite corner of the country. Making full use of the power is hindered by the relatively inflexible way that China's electricity grid is managed, tailored to the steady output of coal plants rather than more variable and less predictable wind and solar, Myllyvirta said. 'This is an issue that the policymakers have recognized and are trying to manage, but it does require big changes to the way coal-fired power plants operate and big changes to the way the transmission network operates,' he said. 'So it's no small task.' ___
.jpeg&w=3840&q=100)
Miami Herald
an hour ago
- Miami Herald
Red panda known for ‘playful sass' dies, Utah zoo says. She was a guest favorite
An 8-year-old red panda known for her 'playful sass' and 'calm confidence' died after a severe health decline, Utah zookeepers said. Kiaria, a Chinese red panda, came to the Hogle Zoo in November as part of a breeding program by the Association of Zoos and Aquariums' Red Panda Species Survival Plan (SSP), according to an Aug. 18 news release by the Salt Lake City-based zoo. Kiaria had a history of gastrointestinal issues, which are common for red pandas, under human care, but in the recent months, she 'had been eating well, sleeping, and showing her playful personality,' the zoo said. On Aug. 14, her health began to rapidly decline, and after trying various treatments, the veterinary staff determined she would not recover, so she was humanely euthanized, zookeepers said. Gastrointestinal issues are the third-leading cause of death in Chinese red pandas living in North American zoos, SSP Red Panda co-vet advisor James Steeil said in the release. The 'confident' Kiaria, known as the 'boss of the cool room,' became a guest favorite after being debuted in March, the zoo said. She would spend time with William, a 2-year-old Chinese red panda, as part of the breeding program but preferred her own space as red pandas are 'naturally solitary,' the zoo said. Chinese red pandas have reddish coats and stripes on their tails with 'larger bodies and longer fur to help retain warmth,' zookeepers said. The species faces threats of habitat loss and poaching, causing a 40% decline in overall population of Chinese red pandasin the last 20 years, the zoo said. 'It was an immense privilege to have Kiaria in our care. She was a meaningful ambassador for her endangered species, helping to inspire greater understanding and appreciation for red pandas,' zookeepers said.
Los Angeles Times
2 hours ago
- Los Angeles Times
New Report on State of Technology in Value-Based Care Exposes Tech and Data Barriers
Glendale-based Reveleer, a leading value-based care technology platform, in partnership with Mathematica, a policy data and analytics company, has released the '2025 State of Technology in Value-Based Care Report.' The report comes during a pivotal moment in healthcare transformation. While payer and provider alignment around value-based care (VBC) has never been stronger, execution is falling behind. The report reveals that while there is widespread confidence in technology's potential to support value-based care, significant barriers such as fragmented data strategies, uneven AI adoption and insufficient staff training are hindering progress and scalability. The report findings defy a common industry narrative that payers and providers are misaligned on priorities. In fact, 100% of providers and 97% of payers surveyed agree their value-based care goals are strongly aligned. What's missing is synchronized execution. Despite shared vision, payers and providers are operating in parallel rather than in concert, pointing to an inefficiency that limits the impact of technology investments and makes scale more difficult. Meanwhile, momentum continues to build: 92% of payers and 81% of providers surveyed saw their VBC contracts grow in the past 12 months. And even more expect growth ahead, with 94% of payers and 83% of providers forecasting increases in the next 12 months. But if execution continues to lag behind ambition, progress may stall before it can transform care. 'To realize the full potential of value-based care, payers and providers must collaborate at scale,' said Jay Ackerman, CEO of Reveleer. 'The good news is payers and providers are finally rowing in the same direction. But if they don't row in sync, we won't move forward. This report points to a clear call to action. The alignment is there, and the tools are ready. Tighter collaboration and true transformation are within reach.' Data management is viewed as a strategic asset by virtually every organization surveyed. 97% of providers and 96% of payers agree that a strong data management approach gives them a competitive edge in the marketplace. Yet behind that confidence lies significant operational fragmentation. Only a third of surveyed providers (33%) and payers (31%) rate their data integration capabilities as 'excellent.' Yet only about half (46% of providers and 53% of payers) are very confident in the accuracy and completeness of the patient data they use in VBC initiatives. This gap between perception and precision signals a major vulnerability in scaling VBC effectively and safely. Every payer and provider surveyed reports using AI. And most agree it's delivering results: 96% of both payers and providers agree their approach to AI adoption and implementation has given them a competitive advantage, and more than 80% of each report seeing positive impacts, including: But enthusiasm hasn't translated into full commitment. Only 40% of payers and 38% of providers say they are fully committed to AI adoption. Just 21% of payers and 29% of providers report a significant increase in AI use in the past 12 months. Underlying this hesitation are concerns about AI hallucinations, algorithmic transparency and the ethics of AI-assisted decisions without human oversight. These concerns don't negate AI's value, but they do signal the need for more robust frameworks for responsible adoption. Despite confidence in AI's promise, organizations are underinvesting in the people who need to use it. While all organizations surveyed offer at least some AI training, only 30% of payers and 32% of provider organizations offer extensive training programs. This lack of preparation is a likely contributor to AI hesitancy and a barrier to scaling its use. As the pressure to improve outcomes and reduce costs intensifies, organizations that pair technology with workforce readiness will be better positioned to lead. 'Technology is a powerful enabler, but it's not a magic wand,' said Ngan MacDonald, director of data innovations at Mathematica. 'The path to scalable value-based care demands more than alignment. It demands real investment in data infrastructure, workforce readiness and AI governance. This report highlights where the friction lies and where leaders need to focus next.' Information sourced from Reveleer. To learn more, contact srubin@
